BOULDER, Colo.--(BUSINESS WIRE)--Array BioPharma Inc. (Nasdaq: ARRY) today announced that its scientific team will present clinical data on the MEK inhibitor, ARRY-162 and p38 inhibitor, ARRY-797, at the Annual European Congress of Rheumatology (EULAR) in Barcelona, Spain and the International Association of Inflammation Societies’ (IAIS) 8th World Congress on Inflammation in Copenhagen, Denmark.
